Pfizer has discontinued SUN 1122 phase-III trial for the evaluation of Sutent (sunitinib malate) plus Folfiri versus Folfiri alone, for the first-line treatment of metastatic colorectal cancer.
Data Monitoring Committee (DMC) found that the addition of sunitinib to the chemotherapy regimen Folfiri, would be unable to demonstrate a significant improvement in the primary endpoint of progression-free survival, compared to Folfiri alone.
Mace Rothenberg, Senior Vice President for Clinical Development and Medical Affairs of Oncology, Pfizer, said: “We are disappointed with this result, but trial successes and failures are an integral part of cancer drug development and contribute to a growing body of knowledge on improving patient care.”
“Pfizer remains committed to developing new agents for colorectal and other GI cancers with ongoing clinical studies evaluating other agents in its pipeline. Investigators will be consulted about the status of sunitinib colorectal studies other than the SUN 1122 trial. Pfizer also continues to study sunitinib in late-stage trials as a potential treatment for various other types of cancer,” he added.